Pearl Therapeutics is a privately held company focused on developing distinct combination therapies for the treatment of highly prevalent chronic respiratory diseases, including chronic obstructive pulmonary disease (COPD) and asthma. Pearl's products will offer patients and healthcare providers therapies to achieve better clinical outcomes.
Pearl has an experienced team of inhalation product development experts with a proven track record of developing and commercializing innovative respiratory products. The team is developing a broad portfolio of high-performance metered dose inhaler (MDI) products, with the lead product being a rapid-acting bronchodilator combination for the treatment of COPD.
Pearl's formulations provide better targeting and distribution of drug throughout the lungs, dose after dose under a wide range of patient use scenarios, without the need for complex devices. Offering these therapies in the most familiar delivery format to patients will reinforce learning, aid compliance, and allow patients to seamlessly transition across all treatments and stages of disease, while offering improved clinical outcomes over existing therapeutics via our improved aerosols.
We have a comprehensive clinical development program under way and have completed ten clinical studies in less than five years. We believe the combination of our particle technology and development strategy will help ensure a rapid and more predictable path to commercialization, and put needed therapies into the hands of more patients.